CAS 79778-41-9|Neridronate
| Common Name | Neridronate | ||
|---|---|---|---|
| CAS Number | 79778-41-9 | Molecular Weight | 277.149 |
| Density | 1.7±0.1 g/cm3 | Boiling Point | 600.1±65.0 °C at 760 mmHg |
| Molecular Formula | C6H17NO7P2 | Melting Point | 245° |
| MSDS | ChineseUSA | Flash Point | 316.7±34.3 °C |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | neridronate sodium hydrate |
|---|---|
| Synonym | More Synonyms |
Neridronate BiologicalActivity
| Description | Neridronate is an aminobisphosphonate, licensed in Italy for the treatment of osteogenesis imperfecta (OI) and Paget’s disease of bone (PDB). Neridronate is effective also in other skeletal diseases such as osteoporosis, algodystrophy, hypercalcemia of malignancy, and bone metastases[1][2]. |
|---|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>Others >>Others |
| References | [1]. Gatti D, et al. Clinical development of neridronate: potential for new applications. Ther Clin Risk Manag. 2013;9:139-47. [2]. Guiducci L, et al. Monthly Intramuscular Neridronate for the Treatment of Postmenopausal Osteoporosis: Results of a 6-Year Prospective Italian Study. Int J Endocrinol. 2019 Feb 6;2019:9802827. |
Chemical & Physical Properties
| Density | 1.7±0.1 g/cm3 |
|---|---|
| Boiling Point | 600.1±65.0 °C at 760 mmHg |
| Melting Point | 245° |
| Molecular Formula | C6H17NO7P2 |
| Molecular Weight | 277.149 |
| Flash Point | 316.7±34.3 °C |
| Exact Mass | 277.048035 |
| PSA | 180.93000 |
| LogP | -3.36 |
| Vapour Pressure | 0.0±3.9 mmHg at 25°C |
| Index of Refraction | 1.569 |
| InChIKey | PUUSSSIBPPTKTP-UHFFFAOYSA-N |
| SMILES | NCCCCCC(O)(P(=O)(O)O)P(=O)(O)O |
| Storage condition | 2-8°C |
| Water Solubility | H2O: 8 mg/mL, soluble |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | R22 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
Articles26
More Articles| Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment. Eur. J. Pharm. Biopharm. 76(1) , 120-6, (2010) Recognition of bone mineral by bisphosphonates is crucial to their targeting, efficacy, therapeutic and diagnostic applications, and pharmacokinetics. In a search for rapid and simple NMR approaches t... | |
| Intramuscular neridronate in postmenopausal women with low bone mineral density. Calcif. Tissue Int. 83(5) , 301-7, (2008) Compliance to osteoporosis treatment with oral bisphosphonates is very poor. Intermittent intravenous bisphosphonate is a useful alternative, but this route is not readily available. Neridronate, a ni... | |
| The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone. Mini Rev. Med. Chem. 9(9) , 1052-63, (2009) Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil, a widely used immunosuppressant. Numerous studies have developed limited sampling strategies (LSSs) to predict MPA AUC in sol... |
Synonyms
| (6-Amino-1-hydroxy-1,1-hexanediyl)bis(phosphonic acid) |
| Neridronic |
| 6-amino-1-hydroxyhexane-1,1-diphosphonic acid |
| NERIXIA |
| 6-amino-1-hydroxy-1,1-hexylidenebisphosphonic acid |
| Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis- |
| (6-amino-1-hydroxyhexylidene)bisphosphonate |
| 6-AMINO-1-HYDROXYHEXYLIDENE BISPHOSPHONIC ACID |
| 6-Amino-1-hydroxyhexylidene bisphosphonic acid,Neridronic acid,Nerixia |
| 6-amino-1-hydroxyhexane-1,1-diphosphonate |
| (6-amino-1-hydroxy-1-phosphonohexyl)phosphonic acid |
| (6-Amino-1-hydroxyhexane-1,1-diyl)bis(phosphonic acid) |
| NERIDRONATE |
| Neridronic acid |
